Pharmasyntez and Orchid Pharma entered into agreements regarding the exclusive rights, manufacturing, and supply of Exblifep, pending regulatory review by the EMA and FDA.
1 report, 1 independent
Updated Jul 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pharmasyntez and Orchid Pharma entered into agreements regarding the exclusive rights, manufacturing, and supply of Exblifep, pending regulatory review by the EMA and FDA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Pharmasyntez
Russian pharmaceutical company
Nothing else this week.